KLK3 and pachyonychia congenita: Primary end point will be to determine if there is any improvement in bDFS, defined as prostate-specific antigen (PSA) rising ≥2 ng ml−1 over PSA Nadir, following the Phoenix criteria for biochemical recurrence of PC (after primary RT) in patients treated with prostate SRT plus ADT (ARM A) compared to patients treated with SRT alone (ARM B).